We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency yesterday announced a new system for reporting drug shortages and potential supply disruptions as the COVID-19 pandemic takes a toll on the stock of some critical medicines. Read More
Gilead CEO Daniel O’Day announced that the company is ramping up production of its antiviral remdesivir for COVID-19 and hopes to have 500,000 treatment courses by October, and more than 1 million treatment courses by the end of the year. Read More
Inovio announced yesterday that the FDA signed off on the company’s investigational NDA for its COVID-19 vaccine candidate INO-4800, clearing the way for a clinical trial. Read More
President Trump has reached out to India’s Prime Minister Narendra Modi following India’s export freeze on the COVID-19 treatment hydroxychloroquine, calling for an exception to the country’s new restrictions. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued its recommended conditions for compassionate use of Gilead’s antiviral remdesivir for treatment of COVID-19. Read More